AR044039A1 - Combinaciones antineoplasicas - Google Patents

Combinaciones antineoplasicas

Info

Publication number
AR044039A1
AR044039A1 ARP040101342A ARP040101342A AR044039A1 AR 044039 A1 AR044039 A1 AR 044039A1 AR P040101342 A ARP040101342 A AR P040101342A AR P040101342 A ARP040101342 A AR P040101342A AR 044039 A1 AR044039 A1 AR 044039A1
Authority
AR
Argentina
Prior art keywords
interferon
cci
mammal
combination
neoplasm
Prior art date
Application number
ARP040101342A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR044039A1 publication Critical patent/AR044039A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de una combinación de CCI-779 e interferón alfa (a) en el tratamiento de neoplasmas. Reivindicación 1: Un método para tratar un neoplasma en un mamífero que lo necesita, el cual comprende proporcionar a dicho mamífero una cantidad efectiva de una combinación que comprende CCI-779 e interferón a, en donde ya sea CCI-779, interferón a o ambos son provistos en cantidades subterapéuticamente efectiva. Reivindicación 16: Una composición farmacéutica útil en el tratamiento de un neoplasma en un mamífero que lo necesita, comprendiendo la composición (a) 42-O-(2-hidroxi)etilrapamicina en forma de dosificación unitaria y (b) unidades de interferón a en combinación o asociación con un portador farmacéuticamente aceptable.
ARP040101342A 2003-04-22 2004-04-21 Combinaciones antineoplasicas AR044039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46449803P 2003-04-22 2003-04-22

Publications (1)

Publication Number Publication Date
AR044039A1 true AR044039A1 (es) 2005-08-24

Family

ID=33310901

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101342A AR044039A1 (es) 2003-04-22 2004-04-21 Combinaciones antineoplasicas

Country Status (27)

Country Link
US (1) US20040258662A1 (es)
EP (1) EP1615640B1 (es)
JP (1) JP2006524246A (es)
KR (1) KR20060006058A (es)
CN (1) CN1777424A (es)
AR (1) AR044039A1 (es)
AT (1) ATE352301T1 (es)
AU (1) AU2004231720A1 (es)
BR (1) BRPI0409632A (es)
CA (1) CA2519338A1 (es)
CL (1) CL2004000836A1 (es)
CO (1) CO5630033A2 (es)
CR (1) CR7993A (es)
DE (1) DE602004004520T2 (es)
DK (1) DK1615640T3 (es)
EC (1) ECSP056114A (es)
ES (1) ES2279407T3 (es)
HK (1) HK1081463A1 (es)
MX (1) MXPA05010582A (es)
NO (1) NO20054412L (es)
PL (1) PL1615640T3 (es)
PT (1) PT1615640E (es)
RU (1) RU2005136222A (es)
TW (1) TW200503753A (es)
UA (1) UA80756C2 (es)
WO (1) WO2004093854A2 (es)
ZA (1) ZA200508574B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
CN101137748B (zh) * 2005-03-07 2011-12-14 罗巴斯研究机构 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
US20070104721A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
WO2007056439A1 (en) * 2005-11-08 2007-05-18 Collegium Pharmaceutical, Inc. Salts of methylene blue and its derivatives
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2310011B1 (en) 2008-06-17 2013-07-24 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
SI2326329T1 (sl) 2008-08-04 2017-06-30 Wyeth Llc Antineoplastične kombinacije 4-anilino-3-cianakinolinov in kapecitabina
HRP20230315T1 (hr) 2009-04-06 2023-05-12 Wyeth Llc Režim liječenja raka dojke korištenjem neratiniba
US9278090B2 (en) * 2012-09-05 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preventing the development of mucositis and related disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
DK1318837T3 (da) * 2000-08-11 2005-01-10 Wyeth Corp Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
DE60316798T2 (de) * 2002-06-07 2008-07-24 Waratah Pharmaceuticals, Inc., Toronto Zusammensetzungen und verfahren zur behandlung von diabetes
PT1635830E (pt) * 2002-09-17 2008-12-31 Wyeth Corp Formulação granulada do éster de rapamicina cci-779

Also Published As

Publication number Publication date
NO20054412L (no) 2005-11-21
BRPI0409632A (pt) 2006-04-25
PT1615640E (pt) 2007-04-30
US20040258662A1 (en) 2004-12-23
CL2004000836A1 (es) 2005-03-04
ZA200508574B (en) 2007-04-25
WO2004093854A3 (en) 2005-02-03
EP1615640A2 (en) 2006-01-18
CA2519338A1 (en) 2004-11-04
RU2005136222A (ru) 2006-03-20
UA80756C2 (en) 2007-10-25
ECSP056114A (es) 2006-03-01
WO2004093854A2 (en) 2004-11-04
DK1615640T3 (da) 2007-03-12
CN1777424A (zh) 2006-05-24
CR7993A (es) 2006-05-26
PL1615640T3 (pl) 2007-05-31
ATE352301T1 (de) 2007-02-15
TW200503753A (en) 2005-02-01
KR20060006058A (ko) 2006-01-18
NO20054412D0 (no) 2005-09-23
JP2006524246A (ja) 2006-10-26
DE602004004520D1 (de) 2007-03-15
DE602004004520T2 (de) 2007-11-08
AU2004231720A1 (en) 2004-11-04
MXPA05010582A (es) 2005-11-23
EP1615640B1 (en) 2007-01-24
CO5630033A2 (es) 2006-04-28
ES2279407T3 (es) 2007-08-16
HK1081463A1 (en) 2006-05-19

Similar Documents

Publication Publication Date Title
AR044039A1 (es) Combinaciones antineoplasicas
AR047988A1 (es) Combinaciones antineoplásicas de cci-779 y rituximab
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
AR043403A1 (es) Combinaciones antineoplasticas
UY27720A1 (es) Aroilpiridinonas monocíclicas,
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
AR048502A1 (es) Sinergia terapeutica de compuestos anti-cancer
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
ES2421516T3 (es) Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341
DE602004025698D1 (de) PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
ES2377720T3 (es) Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
AR034746A1 (es) Combinaciones para el tratamiento de trastornos inflamatorios
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
ECSP055840A (es) Derivados de 4 -tetrazolil-4fenilpiperidina para el tratamiento del dolor
CR8673A (es) Compuestos de difenil-ox-indol-2-ona y su uso en el tratamiento del cancer
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
AR052221A1 (es) Metodo para el tratamiento de la enfermedad poliquistosis renal
ECSP056132A (es) Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
ECSP045153A (es) Metodo y composición para aumentar la potencia de un analgésico de narcotico.
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple

Legal Events

Date Code Title Description
FA Abandonment or withdrawal